Navigation Links
Flexible Filling and Adoption of ‘Ready-to-Use’ Technologies to be Discussed by Catalent Biologics at the Pharma Forum
Date:9/11/2019

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Alex Haig, Senior Director, Engineering will present at the Pharma Forum, to be held at the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. 18-19, 2019.

On Wednesday, Sept. 18 at 10:45 a.m., Mr. Haig will present “Flexible Filling and Ready-to-Use Adoption in Biologics – Journey and Lessons Learned,” where he will discuss Catalent’s use of ‘ready-to-use’ (RTU) vials and cartridges and its application of next generation robotics technology for filling flexibility. He will also highlight important design elements that will help define future concepts, and discuss the market-changing technological and supply chain innovations that have been made possible by the RTU packaging components.

Mr. Haig oversees engineering, maintenance, facilities, and large capital projects at Catalent Biologics’ largest facility in Bloomington, Indiana. He joined the company in 2014, with more than 18 years’ experience in drug substance and drug product operations, and provides leadership in aseptic manufacturing, operational excellence, engineering, maintenance, utilities, and capital project management. He has a bachelor’s degree in mechanical engineering from Drexel University, Philadelphia, and a Six Sigma Black Belt certification from Villanova University.

For further information on this event, visit https://biologics.catalent.com/events/pharma-forum. To arrange a meeting with Mr. Haig, contact Richard Kerns at NEPR - richard(at)nepr.agency

About Catalent Biologics
For more than two decades, Catalent Biologics has built capabilities and experience in development, manufacturing, and analytical services for new biological entities, gene therapies, biosimilars, and antibody-drug conjugates. Catalent has worked with 600+ mAbs and 80+ proteins, and more than 115 clinical trials and 11 marketed products have used GPEx® cell line engineering technology. A further 20 commercially-approved products have employed Catalent Biologics’ capabilities through to aseptic fill/finish. Catalent’s latest addition, Paragon Gene Therapy’s AAV development through commercial-scale manufacturing facilities in Baltimore, Maryland, has produced over 100 clinical GMP batches across 40 programs. Using advanced protein improvement technology and tailored solutions from DNA through to clinical and commercial supply, Catalent Biologics brings better biologic treatments to patients, faster. For more information, visit biologics.catalent.com

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists, at more than 35 facilities across five continents, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/flexible_filling_and_adoption_of_ready_to_use_technologies_to_be_discussed_by_catalent_biologics_at_the_pharma_forum/prweb16561430.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. SSCI’s Flexible Scientist Program (FSP) Extends Value-Added Analytical and Solid-State Chemistry Services to Customers
2. Flexible Equipment for Grocery Service Counters and Checkout Weighing Areas Displayed at NACS 2017
3. Global Printed and Flexible Sensor Industry
4. Flexible Equipment for Grocery Service Counters and Checkout Weighing Areas Displayed at NACS 2015
5. The North American flexible display market and is expected to reach $1329.6 million by 2018 - New Report by MicroMarket Monitor
6. Greener, low-cost transistor heralds advance in flexible electronics
7. Future flexible electronics based on carbon nanotubes
8. FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics
9. Cirrascale® Expands Flexible Datacenter Offerings with Support for Intel® Xeon® Processor E5-2600/1600 v3 Product Families
10. Research team finds way to make solar cells thin, efficient and flexible
11. NJIT professor invents a flexible battery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... July 30, 2020 , ... ... for the life sciences industry, today announced the release of its signature ... for Medical Science Liaisons (MSLs) and other field medical professionals. , ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign , ... and prevention of high-burden diseases, and Centric Consulting, a business and technology consulting ... utilize existing data in order to identify and prioritize patients for care. , ...
(Date:7/10/2020)... ... 2020 , ... In most research using the zebrafish model, ... in zebrafish embryos, maintaining optical transparency to facilitate microscopic imaging. Over the past ... the zebrafish model to investigate the causes of leukaemia and its relationship with ...
(Date:7/1/2020)... ... June 29, 2020 , ... MedShift , a ... 2020, despite many obstacles created as a result of COVID-19. As a provider ... partnered medical practices and medical manufacturers by expanding access to device offerings, technology ...
Breaking Biology Technology:
(Date:8/12/2020)... , ... August 12, 2020 , ... ... monitoring systems that are ideal for public health agencies of all sizes. With ... diseases and helping at-risk individuals find appropriate health care, Mosio helps public health ...
(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, ... contract awarded by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) ... develop, optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess suitable to ...
(Date:7/10/2020)... , ... July 08, 2020 , ... ... Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • ... comparability study, but what is the most effective way to complete one? Will ...
Breaking Biology News(10 mins):